GlassScriptPhysician profile
Amy Kim
NPI 1427231216
$7,683.03
in general payments reported to CMS, 2019-2025
9 companies · $3,644 in 2025
The $3,644 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.53 · 2021: $72.69 · 2022: $3,767 · 2023: $14.04 · 2024: $135 · 2025: $3,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,222 · Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,222.00 |
| Food and Beverage | $571.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,725.60 | 2022-2025 | Imfinzi |
| Exelixis INC. | $1,455.00 | 2022 | |
| Madrigal Pharmaceuticals | $166.01 | 2025 | Rezdiffra |
| Abbvie INC. | $146.11 | 2019-2024 | |
| Genmab U.S., INC. | $122.05 | 2024 | Epkinly |
| Genzyme Corporation | $20.99 | 2025 | |
| Intercept Pharmaceuticals, INC. | $16.63 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.17 | 2019 | |
| Shionogi INC | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.